Overview

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Status:
Recruiting

Trial end date:
2027-09-30

Target enrollment:

Participant gender:

Summary

This phase II pediatric MATCH trial studies how well selpercatinib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborator:

Children's Oncology Group